Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Can-Fite Biopharma Ltd Sponsored ADR (Israel)
(NY:
CANF
)
0.3200
-0.0070 (-2.14%)
Streaming Delayed Price
Updated: 10:02 AM EST, Dec 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Can-Fite Biopharma Ltd Sponsored ADR (Israel)
< Previous
1
2
3
4
5
6
7
Next >
Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
June 29, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
June 13, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
June 02, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Recap: Can Fite Biofarma Q1 Earnings
↗
June 01, 2023
Via
Benzinga
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
June 01, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
May 30, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
May 15, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
May 09, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
May 05, 2023
Via
Benzinga
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
May 02, 2023
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers
Via
MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 02, 2023
Via
Benzinga
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
May 02, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
April 24, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
April 13, 2023
It's time for another dive into the biggest pre-market stock movers as we see what's moving the market on Thursday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
April 11, 2023
Via
Benzinga
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
April 10, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Revenue FY22 Revenue Declines 4.7%, Here Is What You Need To Know
↗
March 30, 2023
Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE:CANF) revenues for the year ended December 31, 2022 were $810,000, a decrease of $43,000, or 4.7%, compared to revenues of $853,000 during the twelve months...
Via
Benzinga
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
March 30, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
March 16, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
March 13, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
↗
February 14, 2023
During Tuesday, 40 stocks hit new 52-week lows.
Via
Benzinga
Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo
February 14, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
↗
February 10, 2023
During Friday, 48 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
January 25, 2023
On Wednesday, 22 companies hit new 52-week lows.
Via
Benzinga
Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
January 24, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
January 11, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
January 10, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Stocks That Hit 52-Week Lows On Wednesday
↗
January 04, 2023
On Wednesday, 35 companies reached new 52-week lows.
Via
Benzinga
Can-Fite Announces ADS Ratio Change
December 30, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite's Namodenoson Increases Survival For Most Severe Patients With Advanced Liver Cancer
↗
December 28, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
